The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.

Abstract

We sought to evaluate the indirect impact of ertapenem use for the treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in our hospital on the susceptibility of Pseudomonas aeruginosa to imipenem. The use of ertapenem was mandated for treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in the absence of nonfermenting gram-negative bacilli for 1 year. The use of imipenem was restricted. Imipenem consumption decreased 64.5%. Ertapenem consumption was 42.57 defined daily doses per 1,000 patient-days. None of the 18 P. aeruginosa isolates recovered after ertapenem introduction were imipenem-resistant, compared with 4 of the 20 P. aeruginosa isolates recovered in the previous year.

• Authors: Ana Lucia L Lima, Priscila R Oliveira, Adriana P Paula, Karine Dal-Paz, Flavia Rossi, Arnaldo V Zumiotti
• Journal: Infection control and hospital epidemiology (Infect Control Hosp Epidemiol) Vol. 30 Issue 5 Pg. 487-90 (May 2009) ISSN: 1559-6834 [Electronic] United States
• PMID: 19335227 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• beta-Lactams
• Imipenem
• beta-Lactamases
• Ertapenem

Topics

• Academic Medical Centers
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Brazil
• Cross Infection (drug therapy, microbiology)
• Drug Resistance, Bacterial
• Drug Utilization (statistics & numerical data)
• Ertapenem
• Humans
• Imipenem (pharmacology, therapeutic use)
• Microbial Sensitivity Tests
• Pseudomonas Infections (drug therapy, microbiology)
• Pseudomonas aeruginosa (drug effects, isolation & purification)
• beta-Lactamases (biosynthesis)
• beta-Lactams (pharmacology, therapeutic use)